This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Brentuximab Vedotin or B-CAP in the Treatment of O...
Clinical trial

Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma

Read time: 1 mins
Last updated:11th Jul 2014

The purpose of this trial is to determine

  1. Objective response rate (ORR), defined as the proportion of patients having CR, CRr or PR in the centrally reviewed restaging after six cycles of chemotherapy
  2. Progression-free survival (PFS) 3 years after registration
Category Value
Study start date 2014-07-11

View full details